202 related articles for article (PubMed ID: 22715141)
1. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
Lu H; Ladd J; Feng Z; Wu M; Goodell V; Pitteri SJ; Li CI; Prentice R; Hanash SM; Disis ML
Cancer Prev Res (Phila); 2012 Aug; 5(8):1036-43. PubMed ID: 22715141
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma.
Zhou SL; Yue WB; Fan ZM; Du F; Liu BC; Li B; Han XN; Ku JW; Zhao XK; Zhang P; Cui J; Zhou FY; Zhang LQ; Fan XP; Zhou YF; Zhu LL; Liu HY; Wang LD
Dis Esophagus; 2014; 27(8):790-7. PubMed ID: 24147952
[TBL] [Abstract][Full Text] [Related]
4. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
Dai L; Li J; Ortega R; Qian W; Casiano CA; Zhang JY
J Immunol Res; 2014; 2014():827827. PubMed ID: 24860838
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
6. Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis.
Xia J; Shi J; Wang P; Song C; Wang K; Zhang J; Ye H
Scand J Immunol; 2016 Jun; 83(6):393-408. PubMed ID: 26991924
[TBL] [Abstract][Full Text] [Related]
7. Serum p53 antibodies in correlation to other biological parameters of breast cancer.
Sangrajrang S; Arpornwirat W; Cheirsilpa A; Thisuphakorn P; Kalalak A; Sornprom A; Soussi T
Cancer Detect Prev; 2003; 27(3):182-6. PubMed ID: 12787724
[TBL] [Abstract][Full Text] [Related]
8. The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
Mudenda B; Green JA; Green B; Jenkins JR; Robertson L; Tarunina M; Leinster SJ
Br J Cancer; 1994 Jun; 69(6):1115-9. PubMed ID: 8198980
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a panel of tumor-associated antigens in breast cancer.
Pagaza-Straffon C; Marchat LA; Herrera L; Díaz-Chávez J; Avante MG; Rodríguez YP; Arreola MC; López-Camarillo C
Cancer Biomark; 2020; 27(2):207-211. PubMed ID: 31839604
[TBL] [Abstract][Full Text] [Related]
10. Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.
Kulić A; Sirotković-Skerlev M; Jelisavac-Cosić S; Herceg D; Kovac Z; Vrbanec D
Med Oncol; 2010 Sep; 27(3):887-93. PubMed ID: 19763913
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
[TBL] [Abstract][Full Text] [Related]
12. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum autoantibody levels in the diagnosis of ovarian endometrioma.
Yi YC; Wang SC; Chao CC; Su CL; Lee YL; Chen LY
J Clin Lab Anal; 2010; 24(5):357-62. PubMed ID: 20872572
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer.
Liu W; Wang P; Li Z; Xu W; Dai L; Wang K; Zhang J
Scand J Immunol; 2009 Jan; 69(1):57-63. PubMed ID: 19140877
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.
Laidi F; Bouziane A; Errachid A; Zaoui F
Asian Pac J Cancer Prev; 2016; 17(1):335-9. PubMed ID: 26838233
[TBL] [Abstract][Full Text] [Related]
16. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
Anderson KS; Ramachandran N; Wong J; Raphael JV; Hainsworth E; Demirkan G; Cramer D; Aronzon D; Hodi FS; Harris L; Logvinenko T; LaBaer J
J Proteome Res; 2008 Apr; 7(4):1490-9. PubMed ID: 18311903
[TBL] [Abstract][Full Text] [Related]
17. Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer.
Liu W; De La Torre IG; Gutiérrez-Rivera MC; Wang B; Liu Y; Dai L; Qian W; Zhang JY
Tumour Biol; 2015 Feb; 36(2):1307-12. PubMed ID: 25355596
[TBL] [Abstract][Full Text] [Related]
18. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
Regidor PA; Regidor M; Callies R; Schindler AE
Eur J Gynaecol Oncol; 1996; 17(3):192-9. PubMed ID: 8780917
[TBL] [Abstract][Full Text] [Related]
19. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
Shimizu K; Ueda Y; Yamagishi H
Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
[TBL] [Abstract][Full Text] [Related]
20. Serum p53 auto-antibodies: incidence in familial breast cancer.
Green JA; Mudenda B; Jenkins J; Leinster SJ; Tarunina M; Green B; Robertson L
Eur J Cancer; 1994; 30A(5):580-4. PubMed ID: 8080669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
